Tumor cell and circulating markers in melanoma: Diagnosis, prognosis, and management

Current Oncology Reports

Volumn 7, Issue 5, 2005, Pages 377-382

  Kounalakis, Nicole ^a   Goydos, James S ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANCER TESTIS ANTIGEN; GLYCOPROTEIN GP 100; LACTATE DEHYDROGENASE; MELAN A; MELANOMA ANTIGEN 3; MESSENGER RNA; MICROSATELLITE DNA; MONOPHENOL MONOOXYGENASE; PROTEIN S 100; TUMOR ANTIGEN; TUMOR ANTIGEN 90; TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER STAGING; CORRELATION ANALYSIS; DNA DETERMINATION; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MELANOMA; MELANOMA CELL; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 24944483429     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0065-2     Document Type: Review

References (50)

1. Balch CM, Buzaid AC, Soong SJ, et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-3648.
2. Reintgen D, Cruse CW, Wells K, et al.: The orderly progression of melanoma nodal metastases. Ann Surg 1994, 220:759-767.
3. Pretlow TP, Bailey JM, Herrera GA, et al.: Culture in soft agar of melanoma cells separated from human peripheral blood. Br J Cancer 1986, 53:411-414.
4. Ulmer A, Schmidt-Kittler O, Fischer J, et al.: Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 2004, 10:531-537.
5. Sarantou T, Chi DD, Garrison DA, et al.: Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997, 57:1371-1376.
6. Goydos JS, Ravikumar TS, Germino FJ, et al.: Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg 1998, 187:182-188, discussion 188-190.
7. Goydos JS, Patel KN, Shih WJ, et al.: Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes. J Am Coll Surg 2003, 196:196-204, discussion 204-195.
8. Starz H, Haas CJ, Schulz GM, Balda BR: Tyrosinase RT-PCR as a supplement to histology for detecting melanoma and nevus cells in paraffin sections of sentinel lymph nodes. Mod Pathol 2003, 16:920-929.
9. Ulrich J, Bonnekoh B, Bockelmann R, et al.: Prognostic significance of detecting micrometastases by tyrosinase RT /PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients. Eur J Cancer 2004, 40:2812-2819.
10. Gogas H, Kefala G, Bafaloukos D, et al.: Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br J Cancer 2002, 87:181-186.
11. Jin HY, Yamashita T, Minamitsuji Y, et al.: Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcription-polymerase chain reaction. J Dermatol Sci 2003, 33:169-176.
12. Mellado B, Gutierrez L, Castel T, et al.: Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 1999, 5:1843-1848.
13. Mocellin S, Del Fiore P, Guarnieri L, et al.: Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 2004, 111:741-745.
14. Osella-Abate S, Savoia P, Quaglino P, et al.: Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br J Cancer 2003, 89:1457-1462.
15. Palmieri G, Ascierto PA, Perrone F, et al.: Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003, 21:767-773.
16. Palmieri G, Strazzullo M, Ascierto PA, et al.: Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol 1999, 17:304-311.
17. Quaglino P, Savoia P, Osella-Abate S, Bernengo MG: RT-PCR tyrosinase expression in the peripheral blood of melanoma patients. Expert Rev Mol Diagn 2004, 4:727-741.
18. Ranieri JM, Wagner JD, Wiebke EA, et al.: Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma. Plast Reconstr Surg 2005, 115:1058-1063.
19. Voit C, Kron M, Rademaker J, et al.: Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol 2005, 23:1218-1227.
20. Smith B, Selby P, Southgate J, et al.: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338:1227-1229.
21. Glaser R, Rass K, Seiter S, et al.: Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 1997, 15:2818-2825.
22. Reinhold U, Ludtke-Handjery HC, Schnautz S, et al.: The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997, 108:166-169.
23. Koyanagi K, Kuo C, Nakagawa T, et al.: Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 2005, 51:981-988. Epub 2005 Apr 7.
24. Max N, Wolf K, Spike B, et al.: Nested quantitative real time PCR for detection of occult tumor cells. Recent Results Cancer Res 2001, 158:25-31.
25. Reynolds SR, Albrecht J, Shapiro RL, et al.: Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003, 9:1497-1502.
26. Deichmann M, Benner A, Bock M, et al.: S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999, 17:1891-1896.
27. Eton O, Legha SS, Moon TE, et al.: Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998, 16:1103-1111.
28. Keilholz U, Conradt C, Legha SS, et al.: Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998, 16:2921-2929.
29. Wang TS, Johnson TM, Cascade PN, et al.: Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004, 51:399-405.
30. Deichmann M, Kahle B, Moser K, et al.: Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 2004, 91:699-702.
31. Gaynor R, Irie R, Morton D, Herschman HR: S100 protein is present in cultured human malignant melanomas. Nature 1980, 286:400-401.
32. Harpio R, Einarsson R: S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004, 37:512-518.
33. Wilder PT, Rustandi RR, Drohat AC, Weber DJ: S100B(beta-beta) inhibits the protein kinase C-dependent phosphorylation of a peptide derived from p53 in a Ca2+-dependent manner. Protein Sci 1998, 7:794-798.
34. Jury CS, McAllister EJ, MacKie RM: Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000, 143:269-274.
35. Smit LH, Korse CM, Hart AA, et al.: Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005, 41:386-392.
36. Gupta RK, Morton DL: Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer patients. J Clin Lab Anal 1992, 6:329-336.
37. Kelley MC, Gupta RK, Hsueh EC, et al.: Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J Clin Oncol 2001, 19:1176-1182.
38. Litvak DA, Gupta RK, Yee R, et al.: Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. J Am Coll Surg 2004, 198:27-35.
39. Chung MH, Gupta RK, Essner R, et al.: Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol 2002, 9:120-126.
40. DuClos TW: Function of C-reactive protein. Ann Med 2000, 32:274-278.
41. Mahmoud FA, Rivera NI: The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002, 4:250-255.
42. Tartour E, Dorval T, Mosseri V, et al.: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994, 69:911-913.
43. Ziegler A, Zangemeister-Wittke U, Stahel RA: Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002, 28:255-271.
44. Goydos JS, Mann B, Kim HJ, et al.: Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005, 200:362-370.
45. Palmieri G, Ascierto PA, Cossu A, et al.: Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Res 2003, 13:167-170.
46. Herbst RA, Mommert S, Casper U, et al.: 11q23 allelic loss is associated with regional lymph node metastasis in melanoma. Clin Cancer Res 2000, 6:3222-3227.
47. Herbst RA, Weiss J, Ehnis A, et al.: Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res 1994, 54:3111-3114.
48. Fujiwara Y, Chi DD, Wang H, et al.: Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res 1999, 59:1567-1571.
49. Taback B, Fujiwara Y, Wang HJ, et al.: Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 2001, 61:5723-5726.
50. Taback B, O'Day SJ, Boasberg PD, et al.: Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 2004, 96:152-156.